No 1 Date of announcement 2026/01/05 Time of announcement 17:11:53 Addresser Shu-Ling Cheng Addresser’s Position President Addresser’s Phone Number 02-26558860 Subject Bonvadis topical cream received medical device marketing authorization approval for all indications in wounds by EDA Egypt. To which item it meets Subparagraph 10 Date of events 2026/01/05 Statement Date of occurrence of...Read More
No 1 Date of announcement 2025/12/19 Time of announcement 17:51:27 Addresser Shu-Ling Cheng Addresser’s Position President Addresser’s Phone Number 02-26558860 Subject Bonvadis topical cream received medical device import license for all indications in wounds for India To which item it meets Subparagraph 10 Date of events 2025/12/19 Statement Date of occurrence of the event:2025/12/19...Read More
No 1 Date of announcement 2025/12/17 Time of announcement 16:39:53 Subject Oneness announces information about the third investor conference in 2025. To which item it meets paragraph 12 Date of events 2025/12/24 Statement Date of institutional investor conference: 2025/12/24 Time of institutional investor conference: 15:00 (GMT+8) Location of institutional investor conference: Online Investor Conference...Read More
No 1 Date of announcement 2025/11/25 Time of announcement 16:45:40 Subject Oneness Biotech Co., Ltd. receives a Korean patent titled “TREATING IGE-MEDIATED ALLERGIC DISEASES” on FB825. To which item it meets Subparagraph 53 Date of events 2025/11/25 Statement Date of occurrence of the event: 2025/11/25 Company name: ONENESS BIOTECH CO., LTD Relationship to the...Read More
No 1 Date of announcement 2025/11/12 Time of announcement 16:54:15 Subject Oneness Biotech Co., Ltd. receives a Canadian patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101). To which item it meets Subparagraph 53 Date of events 2025/11/12 Statement Date of occurrence of the event：2025/11/12 Company name: ONENESS BIOTECH...Read More
No 1 Date of announcement 2025/11/10 Time of announcement 16:44:25 Subject The Company’s 2025Q3 consolidated financial statements have been approved by the Board of Directors. To which item it meets Subparagraph 10 Date of events 2025/11/10 Statement Date of the board of directors submitted or approved:2025/11/10 Date of the audit committee approved:2025/11/10 Start and...Read More
